Research Support. (a) Having regard to the resources reasonably available for such purposes, the Operator will cooperate with AHS to provide such participation by its Staff as may be reasonable in relation to the carrying out of research within the Province.
(b) The Operator agrees to promptly notify AHS in the event that it undertakes or agrees to participate in any form of clinical trial, research project, instrument use, or similar activity which in any way relates to the Services provided under this Agreement. The Operator shall, upon request, provide AHS with written evidence of Client disclosure and consent to research.
Research Support. (a) The Service Provider will cooperate with AHS to provide such participation by its Staff as may be reasonable in relation to the carrying out of research according to approved AHS research protocols and confidentiality requirements within the Province of Alberta.
(b) The Service Provider agrees to promptly notify AHS in the event that it undertakes or agrees to participate in any form of clinical trial, research project, instrument use, or similar activity which in any way relates to the Services provided under this Agreement and ensure that it has all necessary approvals for any of the above noted activities. The Service Provider shall, upon request, provide AHS with written evidence of Client disclosure and consent to research.
Research Support. Having regard to the resources reasonably available for such purposes, the Operator will co-operate with the Region to provide such participation by its personnel as may be reasonable in relation to the carrying out of research within the Region.
Research Support. During the Collaboration Term and upon mutual agreement of the Parties, Takeda may provide research support as set forth in this Section 7.1 (“Research Support”) to Ultragenyx, at Ultragenyx’s sole cost. Such Research Support shall be related to the development of Ultragenyx Pipeline Products (in each case, other than Exercised Products) or Licensed Option Products (in each case, in connection with an Option Product License Agreement), and shall include medicinal chemistry, testing of compounds in disease animal models, drug formulation and clinical development support. If Ultragenyx and Takeda agree that Takeda should provide such Research Support, the confidentiality obligations, access to premises, and other details related to Takeda personnel providing such Research Support to Ultragenyx shall be addressed in a separate agreement between the Parties and such personnel.
Research Support. Pursuant to a sponsored research agreement to be negotiated by the Parties, Acorda shall pay Foundation [**] per year for research support for two (2) years beginning the first full calendar year of commercial sales for the Royalty-Bearing Product, Fampridine-SR. Such sponsored research agreement shall include commercially reasonable terms and conditions as are typical for sponsored research agreements of similar nature in the biotechnology industry as discussed and agreed upon in good faith by the Parties, and further, shall provide that the payment for the first year shall be due within sixty (60) days after the commencement of commercial sales for the Royalty-Bearing Product while the second payment shall be due within sixty (60) days after the first anniversary of commercial sales for the Royalty-Bearing Product.
Research Support. Xxxxxxx will provide funding to support Rigel's efforts under the Research Program and 10 FTE'S of Rigel at a rate of US$2,500,000 per year. Such amount shall be paid quarterly in advance.
Research Support. (a) During the Program Term, JT shall provide Gene Logic with financial support for the Research Program for Gene Logic's Scientific FTEs (as documented to the reasonable satisfaction of JT) at a rate of [***] per Scientific FTE. The FTE payment rate payable pursuant to this Section 7.2(a) shall be adjusted annually in proportion to the percentage increase or decrease in the U.S. Consumer Price Index, unless otherwise agreed upon by the parties in writing. The number of Scientific FTEs for each year of the Program Term will be set forth in the applicable Research Plan; provided that such number shall be not less than [***] Scientific FTEs in any one year period.
(b) Research funding payments shall be made in advance in four quarterly payments during each year of the Program Term (i.e., on or before April 1, July 1, October 1 and January 1 of each year for use in the next quarter). An initial payment will be made within 15 days of the Effective Date, pro-rated to cover the remainder of such calendar quarter. The last payment for the Research Program shall be pro-rated to the end of the Program Term.
(c) If the Research Program is terminated by JT pursuant to Section 2.6, JT shall continue to provide Gene Logic with financial support for the terminated Research Program for the number of Scientific FTEs provided in the then applicable Research Plan as otherwise provided in this Section 7.2 until the effective date of the termination following the notice period as provided in Section 2.6; provided, however, that unless JT has exercised its option to commence another Research Program in addition to the Research Program to be terminated, such financial support shall be at [***] of the rate otherwise provided in this Section 7.2 and such support shall be discontinued at the earlier of (i) the Effective Date of another Research Program in addition to the terminated Research Program or (ii) the effective date of the termination of the Research Program following the notice period as provided in Section 2.6.
(d) Gene Logic shall issue signed invoices in advance for each payment due hereunder.
Research Support. LICENSEE agrees to provide research support to Inventor to further develop Invention at Cornell in the amount of [***] total costs per year for four years under a Sponsored Research Agreement for research relating to the further development of the Technology and the Patent Rights licensed under this Agreement, to be negotiated by LICENSEE with the relevant office at Xxxxx Xxxxxxx Medical College.
Research Support. (a) Each of Cornell and LICENSEE acknowledges that successful development of the Inventions will require substantial ongoing research support from LICENSEE to the laboratory of the Cornell Inventors at Cornell. Each research project in the Inventor’s laboratory (each, a “Project”) will be pursuant to a separate research collaboration agreement (an “RCA”) to be negotiated by LICENSEE and/or the Special Purpose Entity with Xxxxxxx’x office of Biopharma Alliances and Research Collaborations. Each RCA will: have its own attached specific research plan and budget; require support for the Project from LICENSEE, the Special Purpose Entity or Affiliates of at least [***]; and be substantially in the form to be attached as Appendix G by the Parties following signing this Agreement after the initial RCA has been negotiated by the Parties.
(b) From and after the Effective Date, LICENSEE, the Special Purpose Entity and/or Affiliates shall provide research support to Inventor’s laboratory pursuant to one or more RCAs in the aggregate funding amount of at least [***] period, provided that in no single calendar year will the aggregate funding amount under all RCAs be less than [***] (the “Research Commitment”).
(c) With regard to patentable inventions (or patent rights) and new know-how or materials (or results) that arise from the performance of an RCA (each, a “Sponsored Invention”), the RCA will provide that:
(i) for so long as LICENSEE together with the Special Entity and Affiliates is, and has been at all times from the Effective Date, in compliance with its payment obligations under the Research Commitment at the time the Sponsored Invention is disclosed to CTL:
(A) for each Sponsored Invention that is either an improvement to, or is dominated by, the Patent Rights or the Nonexclusive Patent Rights or is specifically designed to be used with a Licensed Product such as pre-clinical data or results and manufacturing know-how (each, an “Improvement”), this Agreement shall be amended to include license grants to all such Improvements, upon:
(1) the election of LICENSEE or the Special Purpose Entity, by written notice to CTL within [***] of LICENSEE’s receipt of the disclosure of such Improvement by CTL; and
(2) LICENSEE’s or the Special Purpose Entity’s payment of the relevant amendment fee of [***] for each Improvement that is a patentable invention (or patent rights), and [***] for each Improvement that is know-how or materials (but in no event to include pre-clinica...
Research Support. 8.1. Centry shall support a programme of research work to be carried out principally at the ICR (the “Research Programme”). Centry shall negotiate the specifics of such Research Programme, with a target budget of US$[***] in good faith with the ICR within a reasonable period following the Effective Date. The Parties shared intention is that the Research Programme will be focused on the mechanism of action of CCT361814 and the identification of patient selection biomarkers. Execution of the Research Programme will be overseen by the JDC.
